Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cytosorbents Corp (NASDAQ: CTSO).

Full DD Report for CTSO

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTSO)

Cytosorbents Corp (CTSO) CEO Phillip Chan on Q3 2018 Results - Earnings Call Transcript
Cytosorbents Corp (CTSO) Q3 2018 Earnings Conference Call November 6, 2018 16:45 ET Executives Jeremy Feffer - Investor Relations Phillip Chan - Chief Executive Officer and President Vincent Capponi - Chief Operating Officer Kathy Bloch - Chief Financial Officer Eric Mortense...
Source: SeekingAlpha
Date: November, 06 2018 22:33
Cytosorbents beats by $0.04, revenue in-line
Cytosorbents (NASDAQ: CTSO ): Q3 GAAP EPS of -$0.10 beats by $0.04 . Revenue of $5.74M (+51.1% Y/Y) in-line. Shares -10.5% . Press Release More news on: Cytosorbents Corp, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 06 2018 16:35
CytoSorbents Reports Third Quarter 2018 Financial Results
MONMOUTH JUNCTION, N.J. , Nov. 6, 2018 /PRNewswire/ --  CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around ...
Source: PR Newswire
Date: November, 06 2018 16:15
CytoSorbents to Report Q3 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , Oct. 31, 2018 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its  CytoSorb ®  blood purification technology to treat deadly inflammation in critically-ill and cardiac surge...
Source: PR Newswire
Date: October, 31 2018 07:00
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
MONMOUTH JUNCTION, N.J. , Sept. 20, 2018 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world...
Source: PR Newswire
Date: September, 20 2018 07:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-189.3010.0510.1499.25790,451
2018-05-179.3010.0510.1499.25790,451
2017-02-035.505.505.605.4041,964
2017-02-025.555.555.705.5034,375
2017-02-015.505.705.755.5051,671

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-119,00154,42016.5399Cover
2018-12-104,94143,89811.2556Cover
2018-12-0732,83849,56266.2564Short
2018-12-0621,86150,08743.6461Short
2018-12-0424,20442,66156.7357Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTSO.


About Cytosorbents Corp (NASDAQ: CTSO)

Logo for Cytosorbents Corp (NASDAQ: CTSO)

MEDASORB TECHNOLOGIES CORPORATION is a publicly traded therapeutic device company that has developed a powerful, patented, blood purification technology that can remove unwanted substances from blood and physiologic fluids to treat a number of diseases. CytoSorb TM , the company s flagship product, was designed as a cytokine filter to reduce potentially deadly cytokine storm in critically ill patients with severe sepsis. CytoSorb s blood compatible polymer beads are highly porous, capturing appropriately sized substances in its pores, while letting larger or smaller substances pass around or through. As blood is pumped through a cartridge of these beads using standard dialysis equipment, cytokines and other toxins are captured by the beads and removed from blood. The purified blood is then returned to the patient. CytoSorb TM has shown preliminary clinical benefit in a small human pilot study treated, control in patients with severe sepsis and is currently being used in an up to patient European Sepsis Trial to treat potentially fatal cytokine storm during severe infection and severe sepsis. CytoSorbents, Inc is the operating subsidiary of MedaSorb Technologies Corporation.

 

Contact Information

 

 

Current Management

  • Phillip Chan / CEO
  • Vincent Capponi / COO
  • Robert Bartlett / CMO

Current Share Structure

  • Market Cap: $231,350,043 - 03/20/2018
  • Issue and Outstanding: 29,471,343 - 02/28/2018

 


Recent Filings from (NASDAQ: CTSO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 25 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 25 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 25 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018

 

 


Daily Technical Chart for (NASDAQ: CTSO)

Daily Technical Chart for (NASDAQ: CTSO)


Stay tuned for daily updates and more on (NASDAQ: CTSO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTSO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTSO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CTSO and does not buy, sell, or trade any shares of CTSO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/